Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,406 across all filing types
Latest filing 2018-03-08 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
PR in English
Investor Presentation Classification · 95% confidence The document is titled "Innate Pharma Hosts R&D Day Today in London" and details the clinical updates, development portfolio, and strategy presentations scheduled for an R&D Day event. It includes speaker lists, webcast/dial-in details, and a schedule of presentations focusing on pipeline progress (monalizumab, IPH5401, IPH4102). This content is characteristic of an investor-focused presentation or event briefing, which aligns best with the Investor Presentation (IP) category. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT), but rather the material or announcement surrounding an investor event.
2018-03-08 English
CP en français
Investor Presentation Classification · 98% confidence The document is titled "Présentation R&D d'Innate Pharma ce jour à Londres" (Innate Pharma R&D Presentation today in London) and details the agenda, speakers, and context for an R&D Day event where the company will present clinical pipeline advancements. This content—a detailed presentation outlining strategy, pipeline progress, and future plans specifically for investors and analysts—aligns perfectly with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT), but rather the material prepared for an investor-focused event.
2018-03-08 French
PR in English
Board/Management Information Classification · 99% confidence The document is a press release dated January 31, 2018, announcing the appointment of Prof. Jean-Yves Blay to the Innate Pharma Supervisory Board. This announcement concerns a change in the company's board of directors or senior management. This directly matches the definition for Board/Management Information (MANG). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT).
2018-01-31 English
CP en français
Board/Management Information Classification · 99% confidence The document is a press release dated January 31, 2018, announcing the appointment of Professor Jean-Yves Blay to the Supervisory Board of Innate Pharma. This type of announcement, detailing changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information'. Therefore, the appropriate filing code is MANG.
2018-01-31 French
PR in English
Regulatory Filings Classification · 90% confidence The document is a press release dated January 30, 2018, announcing a clinical trial collaboration between Innate Pharma and MedImmune (AstraZeneca) regarding the combination of IPH5401 and durvalumab. This type of announcement, detailing strategic business development, clinical partnerships, and pipeline updates, is characteristic of investor relations communications. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it is a formal announcement detailing strategic corporate activity aimed at investors and the public, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general category for corporate news that supports investor relations. Given the options, this is a strategic corporate announcement. While it could potentially be classified as RNS (Regulatory Filings) as a fallback, the content is highly specific to business strategy and clinical development, which often accompanies Investor Presentations (IP) or is released as a general corporate update. However, since it is a press release announcing a specific business event (collaboration) rather than a presentation or a formal financial report, and it is not a transaction in own shares (POS) or director dealing (DIRS), the most appropriate classification among the provided specific options for a major corporate/business development announcement that isn't explicitly M&A or financing is often RNS if no better fit exists, or sometimes it is grouped with Investor Presentations (IP) if it contains strategic forward-looking information. Given the nature of announcing a clinical collaboration and its strategic implications, it is a significant corporate event announcement. Since there is no specific 'Corporate Announcement' code, and it is not a formal financial report, it is best categorized as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck. As a press release detailing strategic business moves, RNS is the safest general regulatory/corporate announcement category.
2018-01-30 English
CP en français
Regulatory Filings Classification · 95% confidence The document is a press release dated January 30, 2018, announcing a clinical collaboration between Innate Pharma and MedImmune (AstraZeneca) to evaluate a combination therapy (IPH5401 and durvalumab) for solid tumors. It details the study design (Phase I/II), the scientific rationale, and provides background information on the compounds and the companies involved. This type of announcement, detailing a new partnership, clinical trial initiation, or significant operational update that is not a full financial report (like 10-K or IR) or a formal regulatory filing like a dividend notice or insider trade, typically falls under a general corporate announcement category. Since it is a press release announcing a strategic development (clinical trial collaboration), it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure, or potentially a Capital/Financing Update (CAP) if the collaboration involved significant financial terms, but the primary focus here is the clinical/strategic development. Given the options, RNS serves as the best general category for non-standard, material corporate news releases that aren't explicitly covered by other codes like ER, DIV, or DIRS. It is not an Earnings Release (ER), nor a formal Annual Report (10-K), nor a specific management discussion (MDA). It is a material announcement released to the public.
2018-01-30 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.